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 2
ABSTRACT 23 
 24 
Although an effective interferon antagonist in human and avian cells, the novel H7N9 25 
influenza virus NS1 protein is defective at inhibiting CPSF30. An I106M substitution in 26 
H7N9 NS1 can restore CPSF30 binding together with the ability to block host gene 27 
expression. Furthermore, a recombinant virus expressing H7N9 NS1-I106M replicates to 28 
higher titers in vivo, and is subtly more virulent, than parental. Natural polymorphisms in 29 
H7N9 NS1 that enhance CPSF30 binding may be cause for concern. 30 
31 
 3
Since early 2013, zoonotic transmission of a novel avian-origin H7N9 influenza A virus 32 
in eastern China has led to at least 441 human infections and 122 deaths (1). Sequence 33 
analyses and functional studies have identified several mammalian-adaptive 34 
polymorphisms in PB2 (20, 33), PA (32), HA and NA (7, 13), that may be responsible for 35 
promoting replication and pathogenicity of this virus in humans. Nevertheless, it is clear 36 
that avian-origin H7N9 has yet to adapt to humans: HA retains its preference for avian 37 
receptors (25, 26, 30, 31), and H7N9 is unable to transmit efficiently between humans. 38 
Identifying sequence changes in H7N9 that may evolve naturally and contribute to future 39 
human-to-human transmission, or which might alter H7N9 virulence, is critical.    40 
 41 
Novel H7N9 virus NS1 is an interferon (IFN)-antagonist in human and chicken cells. 42 
NS1 is a multifunctional virulence factor that plays a major role in antagonizing host IFN 43 
responses during infection [reviewed in (10)]. Notably, this property can vary in 44 
efficiency between virus isolates and between host-cell species’ origin (11, 12, 15, 17, 45 
24). We tested the ability of H7N9 NS1 to limit production of IFNβ in human and avian 46 
cells, and compared it with a panel of NS1 proteins from seasonal human influenza 47 
viruses or other avian H5N1 viruses that have sporadically infected humans since 1997 48 
(Figure 1). Human 293T, or chicken DF-1, cells were transfected with an IFNβ 49 
promoter-driven firefly (FF)-luciferase reporter construct together with expression 50 
plasmids for the NS1 proteins of interest (or GST as a control). For analysis of novel 51 
H7N9, we tested NS1 proteins derived from two different human H7N9 strains 52 
(A/Shanghai/1/2013 [Sh/1] and A/Shanghai/2/2013 [Sh/2]), along with the NS1 from the 53 
closely-related avian H9N2 virus, A/Chicken/Dawang/1/2011 [Dw/11]. Subsequent 54 
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infection with a DI-rich SeV preparation induced robust amounts of IFNβ promoter-55 
driven FF-luciferase activity in GST-expressing human 293T cells, but not in cells 56 
expressing any of the NS1 proteins (Figure 1A). Similar results were observed in chicken 57 
DF-1 cells, albeit the inhibitory impact of all NS1s in this system was less evident 58 
(Figure 1B), possibly due to the absence of chicken RIG-I (2), a key target for NS1 in 59 
humans (19). Notably, Tx/91 NS1, a well characterized and potent inhibitor of general 60 
host gene expression (15), appeared to act as the strongest IFN-antagonist. These data 61 
suggest that the human H7N9 and avian H9N2 precursor NS1s can function as IFN-62 
antagonists in human and chicken cells, a finding in agreement with recent results from 63 
others (14). 64 
 65 
A single I106M substitution in novel H7N9 NS1 enhances CPSF30 binding and 66 
inhibition of host gene expression. Binding of NS1 to cellular CPSF30 contributes to 67 
the global post-transcriptional inhibition of cellular pre-mRNA processing during 68 
infection, and is an additional mechanism by which most human influenza viruses 69 
attenuate host antiviral responses (4, 21, 22). This property of NS1 is not conserved in all 70 
strains (15, 29), and variation in CPSF30 binding has been reported to arise when viruses 71 
are adapted to replicate in certain new host species (5, 23). There are two notable 72 
examples of naturally-occurring influenza viruses that have infected humans but which 73 
encode NS1 proteins unable to inhibit CPSF30: highly-pathogenic avian-origin 1997 74 
H5N1 virus (29) and the swine-origin 2009 pandemic H1N1 virus (11). The defect in 75 
CPSF30 binding maps to slightly different amino-acid positions in the 1997 H5N1 and 76 
2009 pdmH1N1 NS1 proteins (summarized in Figure 2A), and opposite phenotypes have 77 
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been identified for ‘gain-of-function’ substitutions that restore CPSF30 inhibition in these 78 
two viruses: for 1997 H5N1, gain of CPSF30 binding promotes systemic spread of the 79 
virus and increases virulence (27), while for 2009 pdmH1N1, gain of CPSF30 binding 80 
slightly decreases replication and virulence (11). Such phenotypic differences may be due 81 
to the disparate amino-acid substitutions required to restore binding, or the distinct 82 
genetic constellations of the two avian- or swine- origin viruses. Certainly, the impact on 83 
replication and virulence of modulating CPSF30 binding affinity is complex, and 84 
seemingly unpredictable between strains (3, 5, 11, 23, 27, 28). 85 
 86 
Intriguingly, we observed that the novel H7N9 NS1 has the same amino-acid 87 
polymorphisms that weaken CPSF30 binding as the 1997 H5N1 NS1 (Figure 2A). We 88 
tested the co-precipitation of FLAG-tagged CPSF30 with bacterially-expressed 6His-89 
tagged wild-type Sh/2 NS1 (WT), as well as with L103F, I106M or L103F/I106M double 90 
mutant (DM) variants that we predicted might have a different CPSF30-binding profile. 91 
Only a small amount of FLAG-CPSF30 could be precipitated by NS1-WT or NS1-L103F 92 
(Figure 2B). However, FLAG-CPSF30 bound efficiently (and equally) to both NS1-93 
I106M and NS1-DM, suggesting that the H7N9 NS1:CPSF30 interaction is indeed weak, 94 
but can be strengthened by the single I106M substitution. 95 
 96 
To test the ability of H7N9 NS1 to block general host gene expression, we co-transfected 97 
293T cells with a constitutively-active Renilla-luciferase reporter construct (pRL-SV40) 98 
together with each of the indicated Sh/1 NS1 constructs, and measured total Renilla-99 
luciferase activity 24 h later. As shown in Figure 2C, the WT H5N1 VN/04 NS1 (that 100 
binds CPSF30 (29)) efficiently inhibited Renilla-luciferase activity, while the H7N9 NS1-101 
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WT protein (like GST) was deficient in this function. In agreement with our pull-down 102 
studies, NS1-L103F was also unable to inhibit Renilla-luciferase activity, while both 103 
NS1-I106M and NS1-DM proteins efficiently limited activity (Figure 2C). These results 104 
indicate that the single I106M substitution in H7N9 NS1 restores both CPSF30 binding 105 
and the inhibition of cellular gene expression. The I106M substitution specifically 106 
enhanced CPSF30 binding, as no differences were observed between NS1-WT and any of 107 
the NS1 mutants with regards interaction with RIG-I (19) or TRIM25 (6) (Figures 2D & 108 
2E). The I106M substitution also did not impact upon the co-precipitation of Riplet with 109 
NS1 (24), although there was a possible enhancement of this interaction when NS1 110 
constructs contained the L103F substitution (Figure 2F). These data highlight a key 111 
difference with the 1997 H5N1 NS1 protein, where a similar substitution at position 106 112 
was reported to differentially affect CPSF30 and RIG-I binding (3). 113 
 114 
Characterization of an H7N9-based virus expressing NS1-I106M in vitro. Using an 115 
H7N9 reverse genetics system (9), we generated recombinant WT and NS1-I106M 116 
viruses containing the 6 ‘internal’ gene segments of Sh/1 and the HA and NA gene 117 
segments from PR8 (H1N1). This 6+2 strategy using the surface antigens of the 118 
laboratory PR8 H1N1 strain was adopted for risk mitigation purposes given the ‘gain-of-119 
function’ nature of the experiment. The two viruses (rSh/1 (6+2) WT and rSh/1 (6+2) 120 
NS1-I106M) were plaque-purified, and stocks grown and titrated in MDCKs. The NS 121 
genomic segment of each virus from stock aliquots was sequenced to ensure the absence 122 
of additional mutations. Surprisingly, multi-cycle replication experiments revealed that 123 
the recombinant WT and NS1-I106M viruses grew with identical kinetics to each other in 124 
primary differentiated human tracheobronchial epithelial cells (HTBEs; Clonetics, Lonza, 125 
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Walkersville, MD, USA) (Figure 3A). We also assessed ability of the two viruses to 126 
repress IFNβ production using an MDCK cell-line stably expressing firefly luciferase 127 
(FF-Luc) under control of the IFNβ promoter (8). Notably, both WT and NS1-I106M 128 
virus infection led to the same low level (~3-5-fold) induction of the reporter (Figure 129 
3B). The similarity of replication kinetics and IFNβ induction for the two viruses in 130 
primary HTBEs was independently confirmed by qRT-PCR (Figures 3C & 3D). These 131 
data suggest that, in the context of rSh/1 (6+2), the defect in efficient CPSF30 binding by 132 
H7N9 NS1 does not significantly affect virus replication in primary human cells or virus-133 
mediated IFNβ-antagonism in vitro. This may be due to the impact of other IFN-134 
antagonists encoded by the virus [reviewed in (18)], or the observation that H7N9 NS1 is 135 
an efficient IFN-antagonist (14) and retains affinity for RIG-I/TRIM25/Riplet. It is also 136 
possible that partial compensation of the H7N9 NS1:CPSF30 deficiency occurs by the 137 
cognate H7N9 viral polymerase complex, as has been shown for 1997 H5N1 (16, 29). 138 
 139 
An H7N9-based virus expressing NS1-I106M shows enhanced replication and 140 
virulence in vivo. To test whether increased affinity of H7N9 NS1 towards CPSF30 141 
would affect viral replication and pathogenicity in vivo, we determined MLD50 values for 142 
the WT and NS1-I106M viruses in 6-8 week old C57BL/6 mice (Jackson Laboratory, 143 
ME). All procedures were performed in accordance with the IACUC guidelines of Icahn 144 
School of Medicine at Mount Sinai, and animals showing >25% weight loss were 145 
considered to have reached experimental endpoint and were humanely euthanized. 146 
MLD50 values were subsequently calculated according to the method of Reed and 147 
Muench (see Table 1 for a summary of all the data). Even in the highly-virulent rSh/1 148 
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(6+2) background, the NS1-I106M mutation lead to a modest ~2.5-fold increase in 149 
MLD50, and mice infected with the NS1-I106M virus exhibited greater overall mortality 150 
(Figure 3E) and morbidity (as determined by duration and extent of weight loss, and day 151 
of death; Table 1) than mice infected with WT virus. We speculate that the virulence-152 
enhancing impact of H7N9 NS1-I106M may be even more pronounced in the context of 153 
non-PR8 glycoproteins, where the respective WT virus would have a much higher 154 
MLD50. 155 
 156 
To assess replication in vivo, mice were intranasally infected with 500 PFU of each virus 157 
and lungs excised on days 2 and 4 post-infection. Following homogenization and 158 
centrifugation (10,000 x g, 5 min, 4°C), the resulting supernatants were used to determine 159 
viral titer. The NS1-I106M virus replicated to titers >5-fold higher than WT by day 2 (p = 160 
0.0056), while titers at day 4 were similar (Figure 3F). Notably, qRT-PCR analysis of 161 
lung homogenates from independently infected mice suggested a trend for the NS1-162 
I106M virus to induce less IFNβ mRNA than the WT virus, however this was not 163 
statistically significant (Figure 3G). These data indicate that, in contrast to in vitro, ‘gain-164 
of-function’ substitutions in NS1 that enhance CPSF30 binding and inhibition of general 165 
gene expression slightly enhance the replication and pathogenicity of H7N9-based viruses 166 
in vivo. 167 
 168 
Concluding remarks. Continued zoonotic transmission of H7N9 to humans is a 169 
significant cause for concern given the mild to lethal human respiratory disease it causes, 170 
and the fear that it may yet acquire human-to-human transmission. Here, we characterize 171 
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the H7N9 NS1 protein as an efficient IFN-antagonist. Nevertheless, H7N9 NS1 is 172 
defective in binding CPSF30, and is consequently unable to block host-cell gene 173 
expression. We identify the single I106M natural polymorphism found in non-H7N9 174 
strains as a potential ‘gain-of-function’ mechanism by which the H7N9 NS1 could 175 
acquire CPSF30 binding, and provide evidence that this substitution promotes virus 176 
replication and virulence in vivo. These results parallel those found with the 1997 H5N1 177 
virus and the laboratory strain, PR8, where similar substitutions enhanced CPSF30 178 
binding and virulence (27-29). Although polymorphisms in H7N9 NS1 that might restore 179 
CPSF30 binding have yet to be identified in the sequenced strains available, our study 180 
highlights the importance of continued surveillance to monitor potential natural ‘gain-of-181 
function’ mutations in H7N9 NS1 that may impact pathogenicity. 182 
183 
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FIGURE LEGENDS 196 
 197 
Figure 1. The H7N9 NS1 protein is an IFN-antagonist in human and chicken cells. 198 
(A) Human 293T, or (B) chicken DF-1, cells were co-transfected for 16 h with a 199 
pCAGGS expression plasmid encoding the indicated NS1 protein (or GST) together with 200 
a FF-luciferase (FF-Luc) IFNβ-promoter reporter plasmid (p125Luc). After infection 201 
with a DI-rich SeV preparation for a further 12 h, FF-Luc activity was determined. 202 
Results represent the means and standard deviations of triplicate values (normalized to 203 
GST + SeV) obtained in a single experiment, and are representative of two independent 204 
experiments. The NS1 sequences (containing silent splice acceptor mutations to prevent 205 
NEP/NS2 expression (11)) were derived from: A/Texas/36/91 (Tx/91; human seasonal-206 
like H1N1), A/Wyoming/03/03 (Wy/03; human seasonal-like H3N2), A/California/04/09 207 
(Cal/09; human seasonal-like H1N1, previously 2009 pdmH1N1), A/Hong Kong/156/97 208 
(HK/97; representative of the 1997 H5N1 outbreak), A/Vietnam/1203/04 (VN/04; 209 
representative of the 2004 H5N1 outbreak), A/Shanghai/1/2013 (Sh/1; human H7N9), 210 
A/Shanghai/2/2013 (Sh/2; human H7N9) and A/Chicken/Dawang/1/2011 (Dw/11; avian 211 
H9N2 virus with NS1 closely-related to the H7N9 NS1). 212 
 213 
Figure 2. A single I106M substitution in the H7N9 NS1 protein specifically restores 214 
efficient CPSF30 binding and inhibition of host-cell gene expression. (A) Summary 215 
data for a selection of NS1s used in this study. Asterisk denotes predicted binding 216 
affinity based on related H3N2 viruses. (B) Binding of NS1 to CPSF30. 293T cell-lysate 217 
overexpressing FLAG-CPSF30 was mixed with the indicated bacterially-expressed 6His-218 
 12
NS1 protein (WT, L103F, I106M, L103F/I106M [DM]; or 6His-MCS negative control) 219 
and pulled-down using Ni-NTA beads. Precipitates eluted after extensive washing were 220 
analysed by SDS-PAGE and western blotting using anti-NS1 and anti-FLAG antibodies. 221 
(C) NS1-mediated inhibition of general host gene expression. Human 293T cells were 222 
co-transfected with a pCAGGS expression plasmid encoding the indicated NS1 protein 223 
(or GST) together with a constitutively active Renilla-luciferase plasmid. Luciferase 224 
activity was determined 24 h post-transfection. Results show the means and standard 225 
deviations of triplicate values normalized to GST. Statistical significance (**) was 226 
determined using the Student’s t-test. (D-F) Binding of NS1 to cellular factors involved 227 
in the IFN-induction cascade. Experiments were performed as for (B), using 293T 228 
lysates overexpressing FLAG-RIG-I (D), V5-TRIM25 (E), or HA-Riplet (F). Western 229 
blotting was performed using appropriate anti-tag antibodies. 230 
 231 
Figure 3. Characterization of H7N9-based NS1-WT and NS1-I106M viruses in vitro 232 
and in vivo. (A) Virus replication in vitro. Multicycle growth analysis of rSh/1 (6+2) 233 
WT and rSh/1 (6+2) NS1-I106M viruses in primary differentiated human airway 234 
epithelial cells (HTBEs). Data points show mean values and error bars represent standard 235 
deviation. (B) Induction of IFNβ by the recombinant viruses. MDCK-IFNβ-FFluc 236 
cells were infected at an MOI of 2 PFU/cell for 16 h with the indicated virus (or mock) 237 
prior to analysis of luciferase activity. Bars represent mean values (n=3) and error bars 238 
represent SD. (C & D) qRT-PCR analyses of viral replication and IFNβ induction in 239 
vitro. Primary HTBEs were infected at an MOI of 2 PFU/cell and lysed at the times 240 
indicated. Total RNA was extracted, and following reverse transcription using oligo(dT), 241 
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the levels of viral M1 mRNA (C) and IFNβ mRNA (D) were quantified in triplicate by 242 
qPCR. Values were averaged and normalized to actin mRNA. Mean induction levels 243 
relative to mRNA levels in mock-infected cells are shown. Error bars represent standard 244 
deviations. Means and standard deviations were calculated from biological triplicates. (E) 245 
Virulence in mice. Survival data for six-to-eight week-old C57/BL6 mice infected 246 
intranasally with 10 PFU of the indicated virus (20 mice per virus). Body weights were 247 
determined daily for 14 days and mice showing more than 25% weight loss were 248 
considered to have reached the experimental endpoint and were humanely euthanized. (F) 249 
Virus replication in vivo. Six-to-eight week-old C57/BL6 mice were infected 250 
intranasally with 500 PFU of the indicated virus. Lung titers were determined on days 2 251 
and 4 post-infection from 3-4 mice per group. Bars represent mean values. Statistical 252 
significance was determined using the Student’s t-test. (G) qRT-PCR analyses of IFNβ 253 
induction in vivo. Six-to-eight week-old C57/BL6 mice (3-4 mice per group) were 254 
infected intranasally with 500 PFU of the indicated virus for 1 or 3 days. Murine IFNβ 255 
mRNA was quantified from lung homogenates by qRT-PCR as described in panel D. 256 
257 
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Table 1. Characterization of H7N9-based NS1-WT and NS1-I106M viruses in vivo 
Virus MLD50 Dose Survival [%] Median day of death Mean maximum wt loss [%]
[rSh/1 (6+2)] [PFU] [PFU] (no. of survivors/total no. tested) (range) (range) >10% >20%
2 100 (15/15) n/a 8.1 (0.4 - 17.4) 0 (0 - 3) 0 (0)
10 65 (13/20) 11 (10 - 11) 20.5 (2.5 - >25) 5 (0 - 8) 2 (0 - 7)
50 15 (3/20) 9 (8 - 10) 24.6 (19.5 - >25) 10 (4 - 10) 8 (0 - 9)
250 0 (0/5) 9 (8 - 9) >25 (>25) 10 (10 - 11) 9 (9)
1250 0 (0/5) 7 (7 - 8) >25 (>25) 12 (11 - 12) 10 (9 - 10)
2 100 (15/15) n/a 13.5 (1.3 - 21.8) 2 (0 - 4) 0 (0 - 2)
10 20 (4/20) 10 (9 - 11) 22.8 (2.2 - >25) 8.5 (0 - 10) 7 (0 - 8)
50 0 (0/20) 8 (8 - 9) >25 (>25) 10 (10 - 11) 9 (8 - 9)
250 0 (4/4) 7.5 (7 - 8) >25 (>25) 11 (11) 9.5 (9 - 10)
1250 0 (5/5) 7 (6 - 7) >25 (>25) 12 (11 - 12) 10 (10 - 11)
 NS1-WT
NS1-I106M
10.8
4.22
Median no. of days with indicated wt loss (range)
